JP7904995B2 - Nrf2活性化作用を有する含窒素複素環化合物の結晶 - Google Patents

Nrf2活性化作用を有する含窒素複素環化合物の結晶

Info

Publication number
JP7904995B2
JP7904995B2 JP2025528066A JP2025528066A JP7904995B2 JP 7904995 B2 JP7904995 B2 JP 7904995B2 JP 2025528066 A JP2025528066 A JP 2025528066A JP 2025528066 A JP2025528066 A JP 2025528066A JP 7904995 B2 JP7904995 B2 JP 7904995B2
Authority
JP
Japan
Prior art keywords
crystal
powder
diffraction
ray diffraction
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2025528066A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2024262491A5 (cg-RX-API-DMAC7.html
JPWO2024262491A1 (cg-RX-API-DMAC7.html
Inventor
智哉 岩田
則幸 ▲高▼田
将人 河野
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chugai Pharmaceutical Co Ltd
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of JPWO2024262491A1 publication Critical patent/JPWO2024262491A1/ja
Publication of JPWO2024262491A5 publication Critical patent/JPWO2024262491A5/ja
Application granted granted Critical
Publication of JP7904995B2 publication Critical patent/JP7904995B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
JP2025528066A 2023-06-19 2024-06-18 Nrf2活性化作用を有する含窒素複素環化合物の結晶 Active JP7904995B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2023100075 2023-06-19
JP2023100075 2023-06-19
PCT/JP2024/022040 WO2024262491A1 (ja) 2023-06-19 2024-06-18 Nrf2活性化作用を有する含窒素複素環化合物の結晶

Publications (3)

Publication Number Publication Date
JPWO2024262491A1 JPWO2024262491A1 (cg-RX-API-DMAC7.html) 2024-12-26
JPWO2024262491A5 JPWO2024262491A5 (cg-RX-API-DMAC7.html) 2026-06-11
JP7904995B2 true JP7904995B2 (ja) 2026-08-13

Family

ID=93935419

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2025528066A Active JP7904995B2 (ja) 2023-06-19 2024-06-18 Nrf2活性化作用を有する含窒素複素環化合物の結晶

Country Status (9)

Country Link
EP (1) EP4696692A1 (cg-RX-API-DMAC7.html)
JP (1) JP7904995B2 (cg-RX-API-DMAC7.html)
KR (1) KR20260023529A (cg-RX-API-DMAC7.html)
CN (1) CN121152792A (cg-RX-API-DMAC7.html)
AU (1) AU2024314540A1 (cg-RX-API-DMAC7.html)
IL (1) IL324833A (cg-RX-API-DMAC7.html)
MX (1) MX2025014082A (cg-RX-API-DMAC7.html)
TW (1) TW202504613A (cg-RX-API-DMAC7.html)
WO (1) WO2024262491A1 (cg-RX-API-DMAC7.html)

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018181345A1 (ja) 2017-03-28 2018-10-04 武田薬品工業株式会社 複素環化合物
WO2020241853A1 (ja) 2019-05-31 2020-12-03 宇部興産株式会社 ベンゾトリアゾール誘導体
JP2022520442A (ja) 2019-02-15 2022-03-30 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド Nrf2活性剤としてのヒドロキシピリドキシアゼピン
CN114507181A (zh) 2020-11-17 2022-05-17 中国医学科学院药物研究所 含5-取代四氢异喹啉的丙酸类化合物、其药物组合物和应用
JP2023038270A (ja) 2018-08-20 2023-03-16 ヤンセン ファーマシューティカ エヌ.ベー. KEAP1-Nrf2タンパク質-タンパク質相互作用の阻害剤
JP2023524207A (ja) 2020-04-22 2023-06-09 シーフォーエックス・ディスカバリー・リミテッド Nrf2活性化剤としてのテトラヒドロイソキノリン化合物
WO2023132369A1 (ja) 2022-01-07 2023-07-13 中外製薬株式会社 Nrf2活性化作用を有する含窒素複素環化合物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6326507B1 (en) 1998-06-19 2001-12-04 Trustees Of Dartmouth College Therapeutic compounds and methods of use
TWI649330B (zh) 2013-04-24 2019-02-01 艾伯維有限公司 甲基巴多索龍之2,2-二氟丙醯胺衍生物、其多晶形及其使用方法
US20190380992A1 (en) 2014-12-04 2019-12-19 Biogen Ma Inc. Multiple Sclerosis Treatment Regimen Using Dimethyl Fumarate

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018181345A1 (ja) 2017-03-28 2018-10-04 武田薬品工業株式会社 複素環化合物
JP2023038270A (ja) 2018-08-20 2023-03-16 ヤンセン ファーマシューティカ エヌ.ベー. KEAP1-Nrf2タンパク質-タンパク質相互作用の阻害剤
JP2022520442A (ja) 2019-02-15 2022-03-30 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド Nrf2活性剤としてのヒドロキシピリドキシアゼピン
WO2020241853A1 (ja) 2019-05-31 2020-12-03 宇部興産株式会社 ベンゾトリアゾール誘導体
JP2023524207A (ja) 2020-04-22 2023-06-09 シーフォーエックス・ディスカバリー・リミテッド Nrf2活性化剤としてのテトラヒドロイソキノリン化合物
CN114507181A (zh) 2020-11-17 2022-05-17 中国医学科学院药物研究所 含5-取代四氢异喹啉的丙酸类化合物、其药物组合物和应用
WO2023132369A1 (ja) 2022-01-07 2023-07-13 中外製薬株式会社 Nrf2活性化作用を有する含窒素複素環化合物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
NARAYANAN, Dilip et al.,Development of Noncovalent Small-Molecule Keap1-Nrf2 Inhibitors by Fragment-Based Drug Discovery,J. Med. Chem.,2022年,Vol.65,pp.14481-14526

Also Published As

Publication number Publication date
TW202504613A (zh) 2025-02-01
IL324833A (en) 2026-01-01
MX2025014082A (es) 2026-01-07
AU2024314540A1 (en) 2025-11-27
KR20260023529A (ko) 2026-02-20
EP4696692A1 (en) 2026-02-18
JPWO2024262491A1 (cg-RX-API-DMAC7.html) 2024-12-26
CN121152792A (zh) 2025-12-16
WO2024262491A1 (ja) 2024-12-26

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260602

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260602

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20260602

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20260602

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260616

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260630

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260728

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260731